Poor outcomes after Tpoxx mpox treatment mainly seen in those with weak immunity-Mary Van Beusekom, MS
The antiviral drug tecovirimat (brand name, Tpoxx) was prescribed to more than 7,100 US mpox patients in 2022 and 2023, mainly for treating rash and pain in sensitive areas, with most serious adverse events (SAEs)…







